Abstract
Drug-resistance is a major challenge in targeted therapy of EGFR mutated non-small cell lung cancers (NSCLCs). The third-generation irreversible inhib......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
